Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06933420 · ClinicalTrials.gov registry record · NA
Clinical Protocol CERN Feasibility Study
A NA study of Bacterial Vaginosis and Fungal Vaginal Infections, sponsored by Cern Corporation.
- Recruiting
- Registry status
- NA
- Development phase
- 9
- Enrollment target
- 3
- Study locations
NCT06933420: Recruiting NA study of Bacterial Vaginosis and Fungal Vaginal Infections, sponsored by Cern Corporation.
NCT06933420 is a NA study of Bacterial Vaginosis and Fungal Vaginal Infections that is actively recruiting participants, run by Cern Corporation. The registered enrollment target is 9 participants, below the 338-participant average among 15 other Bacterial Vaginosis trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06933420, a NA study of Bacterial Vaginosis and Fungal Vaginal Infections, is actively recruiting participants, sponsored by Cern Corporation.
- RECRUITING
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this clinical trial is to learn if the intravaginal Cern device works to treat bacterial vaginosis and fungal vaginitis in premenopausal women. It will also learn about the safety of the device. The main questions it aims to answer are: Does the device accomplish symptom resolution and negative diagnostic tests post-treatment? What medical problems do participants have when using the intravaginal device? Participants will use the investigational intravaginal device for 5 consecutive days, participate in teleconferences and weekly follow-ups, attend in-clinic visits, and maintain a study diary.
Primary Outcome
Number of participants reporting resolution of vaginal discharge, itching, burning, and/or irritation, assessed using a symptom severity scale with the following levels: none, mild, moderate, or severe. Improvement is defined as a reduction in symptom severity to "none" or "mild" for all reported symptoms.
Conditions Studied
Interventions
- DEVICE Cern Device
Study Locations (3)
California
- Akerman Med - Irvine
- Akerman Med - Orange
- Akerman Med - Santa Ana
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2024-11-06 |
| Est. Completion | 2025-05 |
| Phase | NA |
What NCT06933420 shows while recruiting
NCT06933420 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 338-participant average among 15 other Bacterial Vaginosis trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Bacterial Vaginosis appearing as the primary indexed condition, and to 1 intervention - of which Cern Device is the first listed.
NCT06933420 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06933420 about?
NCT06933420 is a clinical study titled "Clinical Protocol CERN Feasibility Study". The goal of this clinical trial is to learn if the intravaginal Cern device works to treat bacterial vaginosis and fungal vaginitis in premenopausal women. It will also learn about the safety of the device. The main questions it aims to answer are: Does the device accomplish symptom resolution and n...
What is the current status of trial NCT06933420?
This trial is currently recruiting. It is a NA study. The enrollment target is 9 participants. The study started on 2024-11-06. Estimated completion is 2025-05.
What conditions does trial NCT06933420 study?
This clinical trial studies the following conditions: Bacterial Vaginosis, Fungal Vaginal Infections.
What interventions are being tested in trial NCT06933420?
The interventions under investigation include: Cern Device (DEVICE).
Who is sponsoring clinical trial NCT06933420?
This trial is sponsored by Cern Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06933420 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bacterial Vaginosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06933420's enrollment target sits among peer trials
9 15th of 15 higher than 1 of 15 other Bacterial Vaginosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bacterial Vaginosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Vitamin D and Sexual Health
COMPLETED · NA
-
Flourish HEC to Prevent Recurrence of BV
COMPLETED · NA
-
Prospective Data Bank Creation to Study Vaginal Conditions
RECRUITING
-
Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome
RECRUITING · Early Phase 1
-
Single Arm Trial of Menstrual Cups Among Economically Vulnerable Women to Reduce Bacterial Vaginosis and STIs
ACTIVE NOT RECRUITING · Phase 2
-
Treatment of Bacterial Vaginosis (BV) With Tinidazole
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI